Home/Bullfrog AI/Josh Blacher

JB

Josh Blacher

Chief Financial Officer

Therapeutic Areas

Oncology Metabolic Diseases CNS Disorders

Bullfrog AI Pipeline

Drug	Indication	Phase
BF-222	Glioblastoma (initial), other cancers	Preclinical
BF-223	Glioblastoma (initial), other oncology indications	Preclinical
BF-114	Obesity, NAFLD, NASH, Hepatocellular Carcinoma (HCC)	Preclinical

Leadership Team at Bullfrog AI

Chairman and CEO

Praveen Kudithipudi

Chief Business Development Officer

Antonio V. Montano

Chief Marketing Officer & Growth Strategy Leader

JT Koffenberger

Chief Information Officer

VP, Drug Development

Senior Director CNS

Chief Medical Officer

Chief AI Advisor

Strategic Pharma Advisor

Strategic Advisor (Liver Disease)

View full Bullfrog AI profile